UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy

Cancers, 2023-12, Vol.15 (24), p.5709

2023

Link zum Volltext

Verfügbarkeit prüfen

Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma

Cancers, 2024-03, Vol.16 (6), p.1166

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes of monoclonal gammopathy of renal significance (MGRS) without detectable clones

Kidney international reports, 2023-12, Vol.8 (12), p.2765-2777

2023

Link zum Volltext

Verfügbarkeit prüfen

Selinexor: Targeting a novel pathway in multiple myeloma

EJHaem, 2023-08, Vol.4 (3), p.792-810

2023

Link zum Volltext

Verfügbarkeit prüfen

Updates in Plasma Cell Dyscrasias and Related Monoclonal Immunoglobulin-Mediated Renal Disease

Seminars in nephrology, 2022-11, Vol.42 (6), p.151352-151352, Article 151352

2022

Link zum Volltext

Verfügbarkeit prüfen

Determinants of response and resistance to T cell-engaging therapies in multiple myeloma

Nature reviews. Clinical oncology, 2023-08, Vol.20 (8), p.505-506

2023

Link zum Volltext

Verfügbarkeit prüfen

A Mortality Marker: Be Wary of Troponin Elevations in Thrombotic Microangiopathy

Chest, 2017-10, Vol.152 (4), p.A323-A323

2017

Link zum Volltext

Verfügbarkeit prüfen

Synthetic control arms in studies of multiple myeloma and diffuse large B‐cell lymphoma

British journal of haematology, 2022-03, Vol.196 (5), p.1274-1277

2022

Link zum Volltext

Verfügbarkeit prüfen

Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States

Thrombosis and haemostasis, 2020-12, Vol.120 (12), p.1725

2020

Link zum Volltext

Verfügbarkeit prüfen

EXABS-243-CT Late/Deferred ASCT in Myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S134-S136

2023

Link zum Volltext

Verfügbarkeit prüfen

The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement

Blood, 2019-11, Vol.134 (Supplement_1), p.5347-5347

2019

Link zum Volltext

Verfügbarkeit prüfen

Can We Lower the Platelet Threshold of ≥50x10 9/L for Performing a Lumbar Puncture Safely in Patients with Hematological Malignancies?

Blood, 2021-11, Vol.138 (Supplement 1), p.1888-1888

2021

Link zum Volltext

Verfügbarkeit prüfen

Platelet Transfusions Prior to Lumbar Punctures, What Is the Evidence?

Blood, 2021-11, Vol.138 (Supplement 1), p.1916-1916

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8012-8012

2023

Link zum Volltext

Verfügbarkeit prüfen

Can we lower the platelet threshold of ≥ 50 × 109/L for performing a lumbar puncture safely in patients with hematological malignancies?

Annals of hematology, 2023-03, Vol.102 (3), p.663-668

2023

Link zum Volltext

Verfügbarkeit prüfen

P-035 Real world experience of patients treated with teclistamab: a BCMA-directed bispecific T-cell engaging therapy for multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S53-S53

2023

Link zum Volltext

Verfügbarkeit prüfen

P-036 Real world single center expeirence of long-term toxicities with anti-BCMA CAR T-cell therapy in relapsed and refractory multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S54-S54

2023

Link zum Volltext

Verfügbarkeit prüfen

A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma

Expert opinion on drug safety, 2023-11, Vol.22 (11), p.1049-1071

2023

Link zum Volltext

Verfügbarkeit prüfen

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial

The Lancet. Haematology, 2024-06, Vol.11 (6), p.e415-e424

2024

Link zum Volltext

Verfügbarkeit prüfen

P-006: Real world experience of patients treated with idecabtagene vicleucel: a BCMA-directed chimeric antigen receptor T-cell therapy for multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2022-08, Vol.22, p.S39

2022

Link zum Volltext

Verfügbarkeit prüfen

P-016 Disparities in access and practice patterns of BCMA-directed T-cell engager (TCE) therapies in multiple myeloma: a global perspective

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S41-S42

2023

Link zum Volltext

Verfügbarkeit prüfen

P-049 Safety and efficacy of standard of care ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM): real world experience

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S61-S62

2023

Link zum Volltext

Verfügbarkeit prüfen

P-004 Expansion, persistence, and characteristics of autologous, BHV-1100 ARMored memory-like NK cells infused prior to autologous stem cell transplant in MRD+, newly diagnosed multiple myeloma patients

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S34-S35

2023

Link zum Volltext

Verfügbarkeit prüfen

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis

Blood advances, 2023-10, Vol.7 (19), p.5898-5903

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Humans
(10)
Hematology
(9)
Multiple Myeloma
(7)
Oncology
(6)
Multiple Myeloma - Drug Therapy
(4)
Multiple Myeloma - Therapy
(3)
Patients
(3)
Pharmaceutical Industry
(3)
Adult
(2)
Antibodies
(2)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(2)
Antigens
(2)
Apoptosis
(2)
Carfilzomib
(2)
Female
(2)
Health Aspects
(2)
Immunomodulation
(2)
Immunosuppressive Agents
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Clinical Lymphoma, Myeloma And Leukemia
(7)
Blood
(3)
Annals Of Hematology
(2)
Cancers
(2)
Transplantation And Cellular Therapy
(2)
Blood Advances
(1)
Blood Cancer Journal
(1)
British Journal Of Haematology
(1)
Chest
(1)
Ejhaem
(1)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy

Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment

Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma

Clinical outcomes of monoclonal gammopathy of renal significance (MGRS) without detectable clones

Selinexor: Targeting a novel pathway in multiple myeloma

Updates in Plasma Cell Dyscrasias and Related Monoclonal Immunoglobulin-Mediated Renal Disease

Determinants of response and resistance to T cell-engaging therapies in multiple myeloma

A Mortality Marker: Be Wary of Troponin Elevations in Thrombotic Microangiopathy

Synthetic control arms in studies of multiple myeloma and diffuse large B‐cell lymphoma

Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States

EXABS-243-CT Late/Deferred ASCT in Myeloma

The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement

Can We Lower the Platelet Threshold of ≥50x10 9/L for Performing a Lumbar Puncture Safely in Patients with Hematological Malignancies?

Platelet Transfusions Prior to Lumbar Punctures, What Is the Evidence?

Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM)

Can we lower the platelet threshold of ≥ 50 × 109/L for performing a lumbar puncture safely in patients with hematological malignancies?

P-035 Real world experience of patients treated with teclistamab: a BCMA-directed bispecific T-cell engaging therapy for multiple myeloma

P-036 Real world single center expeirence of long-term toxicities with anti-BCMA CAR T-cell therapy in relapsed and refractory multiple myeloma

A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial

P-006: Real world experience of patients treated with idecabtagene vicleucel: a BCMA-directed chimeric antigen receptor T-cell therapy for multiple myeloma

P-016 Disparities in access and practice patterns of BCMA-directed T-cell engager (TCE) therapies in multiple myeloma: a global perspective

P-049 Safety and efficacy of standard of care ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM): real world experience

P-004 Expansion, persistence, and characteristics of autologous, BHV-1100 ARMored memory-like NK cells infused prior to autologous stem cell transplant in MRD+, newly diagnosed multiple myeloma patients

Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis

Suchergebnisse filtern